ASX/Media Release
18 December 2009

ETHICS APPROVAL FOR COMMENCEMENT OF CVac™ PHASE IIb CLINICAL TRIAL

Australian health care company Prima BioMed Ltd (ASX: PRR) (Prima) is pleased to provide the following update on plans for the commencement of its Phase IIb Clinical Trial for the Company's CVac™ ovarian cancer treatment vaccine with the US Food and Drug Administration (FDA).

Prima received clearance from the FDA in August to commence the Phase IIb Trial for CVac™ and since that time the Company has been working on finalising plans for the trial.

The Company can now advise that it has received the ethical approvals so that the clinical trial can commence and this has been to schedule. Following this patient recruitment will begin.

The Company has completed the following tasks in preparation for the Phase IIb Trial:

- Technology transfer of the manufacturing from Australia to the US
- Regulatory interaction in fine tuning the trial
- Design and research of immunological and potency assay
- Doctor and trial nurse investigator meeting
- Independent ethical approval.

Dr. Del Priore, Downtown New York Hospital, commented at the recent investigator meeting "at the practical patient level there are considerable number of patients that are looking for new treatment options. With no real maintenance treatment modularity currently available it is wonderful to provide patients an option with CVac."

The Phase IIb Trial will be conducted on a 60 patient population across multiple centres in the USA/Australia and will be run out of the world-leading Fred Hutchinson Cancer Centre in Seattle. The patient population will be randomised to vaccine treatment arm vs standard of care observation arm. It will be managed by Prima's recently appointed Chief Medical Officer, Dr Neil Frazer and its Head of US Operations, Ms Ginny Raymond and CRO SPRI Clinical Trial team.

The objective of the Phase IIb Trial is to further confirm the ability of CVac™ to reduce the instance of relapse in ovarian cancer patients, control the metastases of the cancer and increase the life expectancy of patients. It will seek to add to the positive efficacy results from CVac™'s Phase IIa Trial on a larger patient population. The Phase IIa Trial was conducted on 28 patients in Australia and was completed in 2007.

Manufacturing of CVac



The commencement of the Phase IIb Trial will signal a major step forward for the Company in its commercialisation pathway for the CVac™ into the multi-billion dollar global pharmacy oncology market.

Mechanism after injection



Prima also plans to commence a Phase III Clinical Trial for CVac™ in Europe in mid-2010. The Phase IIb and Phase III Trials will run concurrently and deliver results from a larger total patient population in a shorter timeframe. Together with CVac™'s recently announced submission for Orphan Drug Status, Prima hopes to expedite the final drug review approval process and fast-track CVac™'s approval for commercial use.

CVac™ is a vaccine therapy treatment for ovarian cancer sufferers that is administered post-surgery and post-chemotherapy to delay the relapse and control the metastases of the cancer. There is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate, and there are currently no maintenance-based therapy products commercially available.

ENDS

Prima BioMed Ltd, Suite 1, 1233 High St, Armadale, VIC 3143
Ph: +61 (0) 3 9824 5254 Fax: +61 (0) 3 9822 7735
www.primabiomed.com.au
ABN: 90 009 237 889

For further information please contact:

Mr Martin Rogers
Executive Director
Prima BioMed
Ph: 0428 268 357
E: martin.rogers@primabiomed.com.au

James Moses
Investor and Media Relations
Mandate Corporate
Ph: 0420 991 574
E: james@mandatecorporate.com.au

Website: www.primabiomed.com.au

About CVac™ Ovarian Cancer Treatment

CVac™ is Prima BioMed's lead product. It is of key importance as there is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate. **CVac™** is a maintenance therapy administered post-surgery and post-chemotherapy to delay relapse and control metastases.

There are currently no products available as maintenance based therapies for ovarian cancer and the global market for ovarian cancer therapeutics was valued at US$2.1b in 2007 and is expected to total US$3.6b by 2010.

Regulatory approval and commercialisation of **CVac™** is the core focus for Prima.

About Prima BioMed

Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology. Prima's lead product is the CVac™ ovarian cancer therapy treatment. It has completed two successful clinical trials and is in the final stages of US FDA approval and eventual commercialisation.

The Company's broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.

.